Shares in Omega Diagnostics have rallied again today following this week's annual results. Watch bosses present the numbers and answer questions.
Omega Diagnostics (LSE:ODX) chief executive Colin King and finance boss Kieron Harbinson present their annual results and answer a range of investor questions. The event, held on the 13 July, is brought to you by our friends at Investor Meet Company.
About the company
Omega Diagnostics Group PLC provides in-vitro diagnostics (IVD) products for use in hospitals, blood banks, clinics and laboratories and specializes in the areas of allergy and autoimmune, food intolerance and infectious diseases. It has three segments: the Allergy and autoimmune division specialise in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases; the Food intolerance division specialises in the research, development, and production of kits to aid the detection of immune reactions to food; and the Infectious disease division specialises in the research, development, production, and marketing of kits to aid the diagnosis of infectious diseases.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.